



Supplementary figure S1: Overview of the protocols. Protocol 1 (A) applied in both males and females BBDPN rats; protocol 2 applied on the MS females (B & D) and for the MS males (C). Blue arrows: subcutaneous injections of β -estradiol 3-benzoate or vehicle. VMR: visceromotor response; BBP-N: BioBreeding diabetes prone normoglycemic rats; PND: post-natal day; MS: maternal separation

Supplementary table S1: qPCR primers

gene	reverse	forward
F2rl1	GCGTGTCCAATCTGCCAATC	TGCTGGGAGGTATCACCCCT
mcpt2	CATGAGCCACACCAGCACAC	GATGAAAAGGCCTGTGTGGACT
ccl2	CTAGTTCTCTGTCTACT	ATGCAGGTCTGTCACT
ccl11	AGATGCACGCTGAAAGCCATAGTC	GGTGCCGATATTCTCCCATAGCAT
il-4	CAGACGTCTTACGGCAACA	AGCACGGAGGTACATCACGT
gper1	TGGTATGACTGCCTTGAGCG	CATGCCTACCCCTGACAGG
gapdh	TCAATGAAGGGTCGTTGATGG	TCTCTGCTCCTCCCTGTTCTAGAG

F2rl1: gene coding for par2 (protease-activated receptor 2); mcpt2: mast cell protease 2; ccl2: gene coding for mcp1 (monocyte chemoattractant protein1); ccl11: gene coding for eotaxin-1; il4: interleukin 4; gper: G-protein coupled estrogen receptor; gapdh: D-glyceraldehyde-3-phosphate dehydrogenase.

Supplementary table S2: Immune cells activation following ovariectomy in female and β -estradiol in males.

	female			male		
	Sham	Ovx	p	vehicle	E2	p
Jejunum EPO	15(6.1-61.6) n=6	38.5(3-76.6) n=8	0.3	53.2(25.1-57.6) n=4	37.6(0.8-56.4) n=6	0.4
Colon EPO	0.3(0.2-0.5) n=6	0.4(0.3-0.6) n=6	0.3	0.2(0.1-0.2) n=4	0.2(0.1-0.3) n=6	0.6
Jejunum β - hexoaminidase	4.2(3.8-7.5) n=7	7.5(4.6-8.2) n=8	0.28	15.9(7.2-19.7) n=4	8.6(4.2-10.7) n=3	0.2
colon β - hexoaminidase	11.2(7.6-16) n=7	14.4(6.2-35) n=7	0.39	17.3(9.9-24.8) n=5	13.6(12-27.3) n=4	0.2

EPO: eosinophil peroxidase; ovx: ovariectomy; E2: β -estradiol. Mann-Whitney t-test.